In vivo evaluation of a biodegradable donut-shaped minitablet for prolonged posterior segment drug delivery in the rabbit eye model

Journal of Pharmaceutical Sciences

Volumn 100, Issue 5, 2011, Pages 1819-1832

  Choonara, Yahya E ^a   Pillay, Viness ^a   Carmichael, Trevor R ^a   Meyer, Leith C R ^a   Du Toit, Lisa C ^a   Naylor, Simon ^a   Wanblad, Carla ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Biodegradable; Ganciclovir; Intraocular drug delivery; Poly(lactic co glycolic acid); Polymeric device; Posterior segment eye disease; Rabbit eye model

Indexed keywords

GANCICLOVIR; POLYGLACTIN; RESOMER;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIODEGRADATION; CILIARY DISK; CONTROLLED STUDY; DONUT SHAPED MINITABLET; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG ISOLATION; DRUG RELEASE; EX VIVO STUDY; HISTOLOGY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; OPHTHALMOSCOPY; PH; RABBIT; RETINA; SLIT LAMP; TOXICITY TESTING; VITREOUS BODY;

EID: 79952233508     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22421     Document Type: Article

References (39)

1. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B, Ashton P, Smith T. 1992. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: Use of an intravitreal device. Arch Ophthalmol 110:188-195.
2. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. 2006. An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm 310:15-24.
3. Choonara YE, Pillay V, Carmichael T, Danckwerts MP. 2007. Studies on a novel doughnut-shaped minitablet for intraocular drug delivery. AAPS PharmSciTech 8:1-7.
4. Harper CA 3rd, Khoobehi B, Peyman GA, Gebhardt BM, Dunlap WA. 1993. Bioavailability of microsphere-entrapped cyclosporine A in the cornea and aqueous of rabbits. Int Ophthalmol 17:337-340.
5. de Rojas Silva MV, Rodriguez-Ares MT, Sanchez-Salorio M, Lamas Diaz MJ, Cuevas Alvarez J, Vila Jato JL, Capeans Tome C. 1999. Efficacy of subconjunctival cyclosporine-containing microspheres on keratoplasty rejection in the rabbit. Arch Clin Exp Ophthalmol 237:840-847.
6. Smith TJ, Pearson PA, Blandford DL, Brown JD, Goins KA, Hollins JL, Schmeisser ET, Glavinos P, Baldwin LB, Ashton P. 1992. Intravitreal sustained-release ganciclovir. Arch Ophthalmol 110:255-258.
7. Hashizoe M, Ogura Y, Takanashi T, Kunou N, Honda Y, Ikada Y. 1997. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr Eye Res 16:633-639.
8. Cunha-Vaz JG. 1997. The blood-ocular barriers: Past, present, and future. Doc Ophthalmol 93:149-57.
9. Foulds WS, Moseley H, Eadie A, et al. 1980. Vitreal, retinal, and pigment epithelial contributions to the posterior blood-ocular barrier. Trans Ophthalmol Soc UK 100;341-342.
10. Akula SK, Peyman GA, Rahimy MH, Hyslop NE, Janney A, Ashton P. 1994. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 78:667-680.
11. Jabs DA, Martin B, Forman MS, Hubbard L, Dunn JP, Kempen JH, Davis JL, Weinberg DV. 2003. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol 135:26-34.
12. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. 2004. Drug delivery systems for vitreoretinal diseases. Prog Retinal Eye Res 23:253-281.
13. Kassem MA, Rahman AAA, Ghora MM, Ahmed MB, Khalil RM. 2007. Pharmaceutical nanotechnology nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 340:126-133.
14. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. 2008. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 68:513-525.
15. Herrero-Vanrell R, Refojo MF. 2001. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Del Rev 52:5-16.
16. Zhou T, Lewis H, Foster RE, Schwendeman SP. 1998. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J Control Rel 55:281-295.
17. European Guideline 3AQ4a. 1992. The use of ionizing radiation in the manufacture of medicinal products. Official Publications in the European Communities, London.
18. Dohadwala AA, Munger R, Damji KF. 1998. Positive correlation between Tonopen intraocular pressure and central corneal thickness. Ophthalmol 105;1849-1854.
19. Lim KS, Wickremasinghe SS, Cordeiro MF, Bunce C, Khaw PT. 2005. Accuracy of intraocular pressure measurements in New Zealand white rabbits. Invest Ophthalmol Vis Sci 46:2419-2423.
20. Kuck JFR. 1975. Composition of the lens, In: Cataract and abnormalities of the lens; Bellows JG, Ed. New York: Grune and Stratton, 6995.
21. Ansel HC, Popovich NG. 1990. Peroral solids, capsules, tablets and controlled release dosage forms. In: Pharmaceutical dosage forms and drug delivery systems; 5th ed. Philadelphia, PA: Lea & Febiger, pp 182-195.
22. Hanson WA. 1982. Handbook of dissolution testing. Springfield, OR: Pharmaceutical Technology Publications.
23. Levy G, Leonards J, Procknal JA. 1965. Development of in vitro tests which correlate quantitatively with dissolution rate-limited drug absorption in man. J Pharm Sci 54:1719-1722.
24. Gibaldi M, Weintraub H. 1970. Quantitative correlation of absorption and in vitro dissolution kinetics of aspirin from several dosage forms. J Pharm Sci 59:725-726.
25. Wagner JG, Nelson E. 1964. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 53:1392-1403.
26. Axelrod J, Reichenthal J. 1953. The fate of caffeine in man and a method for its estimation in biological material. J Pharmacol Exp Ther 107:519-523.
27. Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ, Bradbrook ID. 1981. Plasma and salivary pharmacokinetics of caffeine in man. Eur J Clin Pharmacol 21:45-52.
28. Rall TW. 1980. Central nervous system stimulants. In: The pharmacological basis of therapeutics; Goodman A, Gilman G, Eds. 6th ed. New York: Macmillan Publishing Co. Inc, pp 592-607.
29. Langer R, Peppas N. 1983. Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: A review. Rev Macromol Chem Phys 23:61-126.
30. Heller J. 1984. Biodegradable polymers in controlled drug delivery. Crit Rev Ther Drug Carrier Syst 1:39-90.
31. Deshpande AA, Heller J, Gurny R. 1998. Bioerodible polymers for ocular drug delivery. Crit Rev Ther Drug Carrier Syst 15:381-420.
32. Einmahl S, Zignani M, Varesio E, Heller J, Veuthey JL, Tabatabay C, Gurny R. 1999. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester). Int J Pharm 185:189-198.
33. Gilger BC, Malok E, Cutter KV, Horohov DW, Allen JB. 1999. Characterization of T-lymphocytes in the anterior uvea of eyes with chronic equine recurrent uveitis. Vet Immunol Immunopathol 71:17-28.
34. Duke-Elder WS. 1946. Text book of ophthalmology. London: Kimpton; 1, pp 464-476.
35. Bellows JG. 1944. Cataract and abnormalities of the lens. St Louis: CV Mosby Co; 540-543.
36. Greiner JV, Kopp SJ, Sanders DR, Glonek T. 1981. Organophosphates of the crystalline lens: A nuclear magnetic resonance spectroscopic study. Invest Ophthalmol Vis Sci 21:796-813.
37. Martin JC. 1983. 1-3dihydrodoxy-2-propoxyl-methyl-guanine: A new potent and selective anti-herpes agent. J Med Chem 26:759-761.
38. Tocci, MJ, Livelli TJ, Perry HC, Crumpacker CS, Field AK. 1984. Effects of the nucleoside analogue 2-nor-2'-deoxyguanosone on human cytomegalovirus replication. Antimicrob Agents Chemother 25:247-252.
39. Brockmeier D, Dengler HJ, Voegele D. 1985. In vitro-in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur J Clin Pharmacol 28:291-300.